Julio C. Chavez, Ariel Grajales, J. Sandoval-Sus, Elyce P. Turba, Lisa A. Nodzon, Angimar Uriepero, Mohammad Ammad-ud-din, E. Sahakian, R. Komrokji, L. Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M. Sotomayor, M. Kharfan-Dabaja, C. Bello, Javier Pinilla-Ibarz
{"title":"对未经治疗的慢性淋巴细胞白血病患者联合应用达妥单抗、大剂量甲基强的松龙和来那度胺的长期随访及生物标记物分析","authors":"Julio C. Chavez, Ariel Grajales, J. Sandoval-Sus, Elyce P. Turba, Lisa A. Nodzon, Angimar Uriepero, Mohammad Ammad-ud-din, E. Sahakian, R. Komrokji, L. Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M. Sotomayor, M. Kharfan-Dabaja, C. Bello, Javier Pinilla-Ibarz","doi":"10.1016/j.clml.2024.02.001","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":503375,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"17 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis\",\"authors\":\"Julio C. Chavez, Ariel Grajales, J. Sandoval-Sus, Elyce P. Turba, Lisa A. Nodzon, Angimar Uriepero, Mohammad Ammad-ud-din, E. Sahakian, R. Komrokji, L. Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M. Sotomayor, M. Kharfan-Dabaja, C. Bello, Javier Pinilla-Ibarz\",\"doi\":\"10.1016/j.clml.2024.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":503375,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"17 13\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clml.2024.02.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.clml.2024.02.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis